Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2019 - 2026)

Zentalis Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 25.85% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $121.2 million (down 22.08% YoY), while the FY2025 annual figure was $131.6 million, down 25.45% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $30.0 million, down from $32.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $72.9 million in Q2 2023, with the low at -$142.1 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is $30.4 million (2025), against an average of $10.6 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 686.73% in 2023, then soared 176.75% in 2024.
• Zentalis Pharmaceuticals' Cash from Investing Activities stood at -$11.9 million in 2022, then sank by 253.62% to -$42.1 million in 2023, then soared by 176.75% to $32.3 million in 2024, then gained by 0.51% to $32.4 million in 2025, then retreated by 7.5% to $30.0 million in 2026.
• Business Quant data shows ZNTL's Cash from Investing Activities at $30.0 million in Q1 2026, $32.4 million in Q4 2025, and $28.3 million in Q3 2025.